OMEROS CORP (OMER)
US6821431029 - Common Stock
Thursday's session: top gainers and losers
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Thursday's session: gap up and gap down stocks
Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.
OMER Stock Earnings: Omeros Misses EPS for Q1 2024
OMER stock results show that Omeros missed analyst estimates for earnings per share the first quarter of 2024.
OMER Stock Earnings: Omeros Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Omeros (NASDAQ:OMER) just reported results for the first quarter of 2024.Omeros...
Omeros Corporation Reports First Quarter 2024 Financial Results
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
Commit To Purchase Omeros At $2, Earn 25.2% Annualized Using Options
OMER Stock Earnings: Omeros Misses EPS for Q4 2023
OMER stock results show that Omeros missed analyst estimates for earnings per share the fourth quarter of 2023.
OMER Stock Earnings: Omeros Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Omeros (NASDAQ:OMER) just reported results for the fourth quarter of 2023.Omero...
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade
Discover three stocks with massive upside in oil and gas, data processing and outsourcing services, and pharmaceuticals sectors.
3 Sleeper Stocks Under $15 Ready to Explode by 2029
Discover 3 under-$15 stocks primed for a 2029 explosion, from fintech disruptors to biotech pioneers tackling untreatable rare diseases.
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
Commit To Purchase Omeros At $3, Earn 31.7% Using Options
7 Short-Squeeze Stocks That Are Screaming for Speculation
If you like to march to your own beat even against high pressure, these short-squeeze stocks could be right for you.
Omeros Corporation Reports Third Quarter 2023 Financial Results
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
Notable Monday Option Activity: MARA, LRCX, OMER
Omeros stock plunges 48% on failed Phase 3 study for narsoplimab (OMER)
Omeros (OMER) stock plunged 48% after a Phase 3 study for its drug narsoplimab failed to meet its primary endpoint in the treatment of IgAN. Read more here.